Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer

Journal of the National Cancer Institute

Volumn 103, Issue 23, 2011, Pages 1752-1760

  Monsees, Genevieve M ^a,b   Malone, Kathleen E ^a,b   Tang, Mei Tzu C ^a   Newcomb, Polly A ^a,b   Li, Christopher I ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PROGESTERONE RECEPTOR; TAMOXIFEN; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CONTRALATERAL BREAST CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RACE; SENSITIVITY ANALYSIS;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; NITROGEN COMPOUNDS; ODDS RATIO; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SECONDARY PREVENTION; SEER PROGRAM; TUMOR MARKERS, BIOLOGICAL; WASHINGTON;

EID: 83255173945     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr399     Document Type: Article

References (26)

1. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(10):855-861. (Pubitemid 29508719)
2. Brenner DJ. Contralateral second breast cancers: prediction and prevention. J Natl Cancer Inst. 2010;102(7):444-445.
3. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005;353(6):595-603.
4. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21(11):2188-2194.
5. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840-849.
6. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77-85.
7. Coleman RE. Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer. Nat Clin Pract Endocrinol Metab. 2009;5(2):72-73.
8. Aft R. Bisphosphonates in breast cancer: antitumor effects. Clin Adv Hematol Oncol. 2011;9(4):292-299.
9. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34(5):453-475.
10. Gnant M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets. 2009;9(7):824-833.
11. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010;102(7):1099- 1105.
12. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28(22):3582-3590.
13. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010;28(22):3577-3581.
14. Gnant M. Can oral bisphosphonates really reduce the risk of breast cancer in healthy women? J Clin Oncol. 2010;28(22):3548-3551.
15. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-691.
16. Li CI, Daling JR, Porter PL, Tang M-TC, Malone KE. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res. 2009;69(17):6865-6870.
17. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER Summary Staging Manual-2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001. NIH Pub. No. 01-4969.
18. Seiffert JE, Shambaugh EM, Weiss MA, et al. SEER Program: Comparative Staging Guide for Cancer. Version 1.1. Bethesda, MD: National Cancer Institute; 1993. NIH Pub. No. 93-3640.
19. Havener LA, Hultstrom D. North American Association for Central Cancer Registries: Standards for Cancer Registries Volume II-Data Standards and Data Dictionary. 10th ed. Version 11. Springfield, IL: North American Association of Central Cancer Registries; 2004.
20. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631-641.
21. Coleman R, Woodward E, Brown J, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat. 2011;127(2):429-438.
22. Coleman RE, Thorpe H, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04). Abstract number S4-5. Presented at the 33rd Annual San Antonio Breast Cancer Symposium; October 10, 2010; San Antonio, TX.
23. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer. 2010;102(5):799-802.
24. Vestergaard P, Fischer L, Mele M, Mosekilde L, Christiansen P. Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int. 2011;88(4):255-262.
25. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86(11):1022-1033.
26. Ressler S, Mlineritsch B, Greil R. Zoledronic acid for adjuvant use in patients with breast cancer. Expert Rev Anticancer Ther. 2011;11(3):333-349.